© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 12, 1006-1010,
June 21, 2000
© 2000 Oxford University Press
REPORTS |
Genotype–Phenotype Relationships in U.S. Melanoma-Prone Families With CDKN2A and CDK4 Mutations
Affiliations of authors: A. M. Goldstein, M. C. Fraser, M. A. Tucker (Genetic Epidemiology Branch), J. P. Struewing (Laboratory of Population Genetics), Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; A. Chidambaram, Intramural Research Support Program, Scientific Applications International Corporation, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD.
Correspondence to: Alisa M. Goldstein, Ph.D., National Institutes of Health, Executive Plaza South, Rm. 7004, 6120 Executive Blvd. MSC 7236, Bethesda, MD 20892-7236 (e-mail: goldstea{at}exchange.nih.gov).
Background: Two genes have been implicated in the development of cutaneous malignant melanoma (CMM). CDK4 (the gene encoding cyclin-dependent kinase 4, an oncogene) has exhibited germline mutations found in only three melanoma-prone families to date. CDKN2A is a tumor suppressor gene that encodes p16 (which inhibits activity of the cyclin D1–CDK4 complex) with germline mutations detected in 10%–25% of melanoma-prone families, some of whom are also prone to pancreatic cancer. Methods: We compared 104 CMM patients from 17 CDKN2A families and 12 CMM case subjects from two CDK4 families. We used nonparametric statistics to test for differences in median age at first CMM diagnosis, numbers of CMMs, and numbers of nevi. The three recurrent mutations were haplotyped. All P values were two-sided. Results: The median age at CMM diagnosis (P = .70) and the median numbers of CMMs (P = .73) did not differ between CMM case subjects from CDKN2A versus CDK4 families. Assessment of CMM case subjects from CDKN2A families with and without pancreatic cancer revealed no statistically significant differences in median age at diagnosis (P = .80) or in tumor number (P = .24). There was, however, a statistically significant difference in age-adjusted median numbers of nevi (P = .004), and CMM case subjects from CDKN2A families without pancreatic cancer had greater numbers of nevi. Recurrent CDKN2A mutations were a change from valine to aspartic acid at codon 126 (n = 3) and from glycine to tryptophan at codon 101 (n = 3). Six CDKN2A families had pancreatic cancer. Both CDK4 families carried a mutation resulting in an arginine-to-cysteine substitution at codon 24. Analyses of recurrent CDKN2A and CDK4 mutations suggested common haplotypes. Conclusions: The recurrent CDKN2A mutations were observed in families with and without pancreatic cancer, which suggests that other factors may be involved in the development of pancreatic cancer. Despite hypothetical differences in the mechanisms of action between CDKN2A and CDK4, clinical factors were indistinguishable between CMM case subjects from CDKN2A versus CDK4 families.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Figl, R. K. Thirumaran, S. Ugurel, A. Gast, K. Hemminki, R. Kumar, and D. Schadendorf Multiple Melanomas After Treatment for Hodgkin Lymphoma in a Non-Dutch p16-Leiden Mutation Carrier With 2 MC1R High-Risk Variants Arch Dermatol, April 1, 2007; 143(4): 495 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Goldstein, M. Chan, M. Harland, N. K Hayward, F. Demenais, D Timothy Bishop, E. Azizi, W. Bergman, G. Bianchi-Scarra, W. Bruno, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents J. Med. Genet., February 1, 2007; 44(2): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Goldstein, M. Chan, M. Harland, E. M. Gillanders, N. K. Hayward, M.-F. Avril, E. Azizi, G. Bianchi-Scarra, D. T. Bishop, B. Bressac-de Paillerets, et al. High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL. Cancer Res., October 15, 2006; 66(20): 9818 - 9828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Earl, L. Yan, L. J. Vitone, J. Risk, S. J. Kemp, C. McFaul, J. P. Neoptolemos, W. Greenhalf, for the European Registry of Hereditary Pancreatit, R. Kress, et al. Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1948 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Berwick, I. Orlow, A. J. Hummer, B. K. Armstrong, A. Kricker, L. D. Marrett, R. C. Millikan, S. B. Gruber, H. Anton-Culver, R. Zanetti, et al. The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1520 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Chaudru, K. Laud, M.-F. Avril, A. Miniere, A. Chompret, B. Bressac-de Paillerets, F. Demenais, and The French Familial Melanoma Study Group Melanocortin-1 Receptor (MC1R) Gene Variants and Dysplastic Nevi Modify Penetrance of CDKN2A Mutations in French Melanoma-Prone Pedigrees Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2384 - 2390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Goldstein, M. T. Landi, S. Tsang, M. C. Fraser, D. J. Munroe, and M. A. Tucker Association of MC1R Variants and Risk of Melanoma in Melanoma-Prone Families with CDKN2A Mutations Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2208 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Goldstein, J P Struewing, M C Fraser, M W Smith, and M A Tucker Prospective risk of cancer in CDKN2A germline mutation carriers J. Med. Genet., June 1, 2004; 41(6): 421 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Chaudru, A. Chompret, B. Bressac-de Paillerets, A. Spatz, M.-F. Avril, and F. Demenais Influence of Genes, Nevi, and Sun Sensitivity on Melanoma Risk in a Family Sample Unselected by Family History and in Melanoma-Prone Families J Natl Cancer Inst, May 19, 2004; 96(10): 785 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ghiorzo, L. Pastorino, L. Bonelli, R. Cusano, A. Nicora, S. Zupo, P. Queirolo, M. Sertoli, V. Pugliese, and G. Bianchi-Scarra INK4/ARF germline alterations in pancreatic cancer patients Ann. Onc., January 1, 2004; 15(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Bishop, F. Demenais, A. M. Goldstein, W. Bergman, J. N. Bishop, B. B.-d. Paillerets, A. Chompret, P. Ghiorzo, N. Gruis, J. Hansson, et al. Geographical Variation in the Penetrance of CDKN2A Mutations for Melanoma J Natl Cancer Inst, June 19, 2002; 94(12): 894 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Smeds, P. Berggren, X. Ma, Z. Xu, K. Hemminki, and R. Kumar Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16INK4a and p14ARF ) and p53 genes are major targets for inactivation Carcinogenesis, April 1, 2002; 23(4): 645 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Goldstein and M. A. Tucker Genetic Epidemiology of Cutaneous Melanoma: A Global Perspective Arch Dermatol, November 1, 2001; 137(11): 1493 - 1496. [Full Text] [PDF]
|
|
|
|
 |
|
 E EFTHIMIOU, T CRNOGORAC-JURCEVIC, N R LEMOINE, and T A BRENTNALL Inherited predisposition to pancreatic cancer Gut, February 1, 2001; 48(2): 143 - 147. [Full Text] [PDF]
|
|